A case of a patient treated with percutaneous edge-to-edge mitral valve repair, percutaneous left atrial appendage occlusion and implantable cardioverter-defibrillator
Abstract
The article presents the case of a 55-year-old woman who suffered from anterior myocardial infarction and
chronic complications of the underlying disease, heart failure with reduced left ventricular ejection fraction,
severe secondary mitral regurgitation, and paroxysmal atrial fibrillation. Due to the severity of symptoms,
which persisted despite the optimal pharmacotherapy, after exclusion of reversible causes, the patient was
qualified for different advanced percutaneous treatment methods. Within two years from the onset of the
disease, three percutaneous procedures were performed: mitral valve correction with the MitraClip system,
left atrial appendage occlusion using the Watchman system, and implantation of cardioverter-defibrillator.
Keywords: heart failure with reduced ejection fractionmitral regurgitationpercutaneous edge-to-edge mitral valve repairleft atrial appendage occlusionimplantable cardioverter-defibrillator
References
- Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007; 93(9): 1137–1146.
- Redfield MM, Jacobsen SJ, Burnett JC, et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003; 289(2): 194–202.
- Bleumink GS, Knetsch AM, Sturkenboom MC, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J. 2004; 25(18): 1614–1619.
- Ceia F, Fonseca C, Mota T, et al. EPICA Investigators. Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. Eur J Heart Fail. 2002; 4(4): 531–539.
- Maggioni AP, Dahlström U, Filippatos G, et al. Heart Failure Association of the European Society of Cardiology (HFA). EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2013; 15(7): 808–817.
- Baumgartner H, Falk V, Bax JJ, et al. ESC Scientific Document Group, ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017; 38(36): 2739–2791.
- Holmes DR, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014; 64(1): 1–12.
- Holmes DR, Doshi SK, Kar S, et al. Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis. J Am Coll Cardiol. 2015; 65(24): 2614–2623.
- Reddy VY, Möbius-Winkler S, Miller MA, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol. 2013; 61(25): 2551–2556.
- Moss AJ, Zareba W, Hall WJ, et al. Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002; 346(12): 877–883.
- Desai AS, Fang JC, Maisel WH, et al. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA. 2004; 292(23): 2874–2879.
- Bardy G, Lee K, Mark D, et al. Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart Failure. New England Journal of Medicine. 2005; 352(3): 225–237.